Literature DB >> 33086403

Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19.

Carmen Fernández-Capitán1, Raquel Barba2, María Del Carmen Díaz-Pedroche3, Patricia Sigüenza4, Pablo Demelo-Rodriguez5, Carmine Siniscalchi6, José María Pedrajas7, Ana I Farfán-Sedano8, Pavel Eduardo Olivera9, Covadonga Gómez-Cuervo3, Pilar Llamas10, Paula Villares11, Olivier Sanchez12, Raquel López-Reyes13, Judith Catella14, Behnood Bikdeli15,16,17, Ido Weinberg18, Alfonso J Tafur19, David Jiménez20,21,22, Manuel Monreal23,24,22.   

Abstract

Venous thromboembolism (VTE) is common in patients with coronavirus disease-2019 (COVID-19). However, limited data exist on patient characteristics, treatments, and outcomes. To describe the clinical characteristics, treatment patterns, and short-term outcomes of patients diagnosed with VTE during hospitalization for COVID-19. This is a prospective multinational study of patients with incident VTE during the course of hospitalization for COVID-19. Data were obtained from the Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) registry. All-cause mortality, VTE recurrences, and major bleeding during the first 10 days were separately investigated for patients in hospital wards versus those in intensive care units (ICUs). As of May 03, 2020, a total number of 455 patients were diagnosed with VTE (83% pulmonary embolism, 17% isolated deep vein thrombosis) during their hospital stay; 71% were male, the median age was 65 (interquartile range, 55-74) years. Most patients (68%) were hospitalized in medical wards, and 145 in ICUs. Three hundred and seventeen (88%; 95% confidence interval [CI]: 84-91%) patients were receiving thromboprophylaxis at the time of VTE diagnosis. Most patients (88%) received therapeutic low-molecular-weight heparin, and 15 (3.6%) received reperfusion therapies. Among 420 patients with complete 10-day follow-up, 51 (12%; 95% CI: 9.3-15%) died, no patient recurred, and 12 (2.9%; 95% CI: 1.6-4.8%) experienced major bleeding. The 10-day mortality rate was 9.1% (95% CI: 6.1-13%) among patients in hospital wards and 19% (95% CI: 13-26%) among those in ICUs. This study provides characteristics and early outcomes of patients diagnosed with acute VTE during hospitalization for COVID-19. Additional studies are needed to identify the optimal strategies to prevent VTE and to mitigate adverse outcomes associated. Thieme. All rights reserved.

Entities:  

Year:  2020        PMID: 33086403     DOI: 10.1055/s-0040-1718402

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  14 in total

1.  Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry.

Authors:  Behnood Bikdeli; César Caraballo; Javier Trujillo-Santos; Jean Philippe Galanaud; Pierpaolo di Micco; Vladimir Rosa; Gemma Vidal Cusidó; Sebastian Schellong; Meritxell Mellado; María Del Valle Morales; Olga Gavín-Sebastián; Lucia Mazzolai; Harlan M Krumholz; Manuel Monreal
Journal:  JAMA Cardiol       Date:  2022-08-01       Impact factor: 30.154

2.  Age-Adjusted D-Dimer Levels May Improve Diagnostic Assessment for Pulmonary Embolism in COVID-19 Patients.

Authors:  Michał Machowski; Anna Polańska; Magdalena Gałecka-Nowak; Aleksandra Mamzer; Marta Skowrońska; Katarzyna Perzanowska-Brzeszkiewicz; Barbara Zając; Aisha Ou-Pokrzewińska; Piotr Pruszczyk; Jarosław D Kasprzak
Journal:  J Clin Med       Date:  2022-06-09       Impact factor: 4.964

Review 3.  Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.

Authors:  Azita H Talasaz; Parham Sadeghipour; Hessam Kakavand; Maryam Aghakouchakzadeh; Elaheh Kordzadeh-Kermani; Benjamin W Van Tassell; Azin Gheymati; Hamid Ariannejad; Seyed Hossein Hosseini; Sepehr Jamalkhani; Michelle Sholzberg; Manuel Monreal; David Jimenez; Gregory Piazza; Sahil A Parikh; Ajay J Kirtane; John W Eikelboom; Jean M Connors; Beverley J Hunt; Stavros V Konstantinides; Mary Cushman; Jeffrey I Weitz; Gregg W Stone; Harlan M Krumholz; Gregory Y H Lip; Samuel Z Goldhaber; Behnood Bikdeli
Journal:  J Am Coll Cardiol       Date:  2021-03-11       Impact factor: 24.094

4.  Long-term follow-up of patients with venous thromboembolism and COVID-19: Analysis of risk factors for death and major bleeding.

Authors:  Pablo Demelo-Rodríguez; Lucía Ordieres-Ortega; Zichen Ji; Jorge Del Toro-Cervera; Javier de Miguel-Díez; Luis A Álvarez-Sala-Walther; Francisco Galeano-Valle
Journal:  Eur J Haematol       Date:  2021-03-03       Impact factor: 3.674

5.  Incidence and clinical profile of venous thromboembolism in hospitalized COVID-19 patients from Madrid region.

Authors:  Karmele Arribalzaga; Inés Martínez-Alfonzo; Carola Díaz-Aizpún; Isabel Gutiérrez-Jomarrón; Mario Rodríguez; Nerea Castro Quismondo; Elia Pérez-Fernández; Diego Velasco-Rodríguez; Elvira Gómez; Begoña Fernández; Alba Vilches; Sara Martín-Herrero; Lucía Castilla; María Jesús Blanco; María Del Mar Gutiérrez; Isabel Rivas; Cristina Pascual; Belén Rosado; Elena Sola; Rosa Vidal-Laso; Susana Asenjo; María Asunción Mora Casado; Laurentino Benito-Parra; Itziar Carmona; Karen Marín; Natalia Acedo; Natalia García-León; Alexis Marcheco; Carolina Guillén; Cristina Fernández; Ramón Rodríguez; Laura Pardo; Pablo Silva; Laura Montero; Mar Meijón; Pilar Massó; Pilar Llamas-Sillero
Journal:  Thromb Res       Date:  2021-05-08       Impact factor: 3.944

Review 6.  Heparin and SARS-CoV-2: Multiple Pathophysiological Links.

Authors:  Pierpaolo Di Micco; Egidio Imbalzano; Vincenzo Russo; Emilio Attena; Vincenzo Mandaliti; Luana Orlando; Maurizio Lombardi; Gianluca Di Micco; Giuseppe Camporese; Saverio Annunziata; Gaetano Piccinocchi; Walter Pacelli; Michele Del Guercio
Journal:  Viruses       Date:  2021-12-11       Impact factor: 5.048

7.  Validation of a Prognostic Score to Identify Hospitalized Patients with COVID-19 at Increased Risk for Bleeding.

Authors:  Pablo Demelo-Rodriguez; Francisco Galeano-Valle; Lucía Ordieres-Ortega; Carmine Siniscalchi; Mar Martín Del Pozo; Ángeles Fidalgo; Aída Gil-Díaz; José Luis Lobo; Cristina De Ancos; Manuel Monreal
Journal:  Viruses       Date:  2021-11-15       Impact factor: 5.048

Review 8.  [Persistent COVID-19 syndrome. A narrative review].

Authors:  A López-Sampalo; M R Bernal-López; R Gómez-Huelgas
Journal:  Rev Clin Esp       Date:  2021-11-15       Impact factor: 3.064

9.  Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis.

Authors:  David Jiménez; Aldara García-Sanchez; Parth Rali; Alfonso Muriel; Behnood Bikdeli; Pedro Ruiz-Artacho; Raphael Le Mao; Carmen Rodríguez; Beverley J Hunt; Manuel Monreal
Journal:  Chest       Date:  2020-11-17       Impact factor: 9.410

10.  Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.

Authors:  Behnood Bikdeli; Azita H Talasaz; Farid Rashidi; Babak Sharif-Kashani; Mohsen Farrokhpour; Hooman Bakhshandeh; Hashem Sezavar; Ali Dabbagh; Mohammad Taghi Beigmohammadi; Pooya Payandemehr; Mahdi Yadollahzadeh; Taghi Riahi; Hossein Khalili; Sepehr Jamalkhani; Parisa Rezaeifar; Atefeh Abedini; Somayeh Lookzadeh; Shaghayegh Shahmirzaei; Ouria Tahamtan; Samira Matin; Ahmad Amin; Seyed Ehsan Parhizgar; David Jimenez; Aakriti Gupta; Mahesh V Madhavan; Sahil A Parikh; Manuel Monreal; Naser Hadavand; Alireza Hajighasemi; Majid Maleki; Saeed Sadeghian; Bahram Mohebbi; Gregory Piazza; Ajay J Kirtane; Gregory Y H Lip; Harlan M Krumholz; Samuel Z Goldhaber; Parham Sadeghipour
Journal:  Thromb Res       Date:  2020-09-24       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.